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Introduction
In 1988, McNeal (1) described three glandular regions of the prostate: the peripheral (PZ), the central and the transition zones (TZ), which respectively comprise ~70%, 25% and 5% of the prostatic glandular tissue. The PZ is the site of origin of most carcinomas (70-80%), but some arise in the TZ, and (rarely) in the central zone (2, 3) . Morphological differences between tumors in these zones have been observed (2) , and markers of poor prognosis, such as high Gleason score, are observed at higher rates among PZ cancers (3, 4) , which are therefore thought to be more aggressive. Distinct tumor subtypes may arise in each zone, potentially through unique etiologic pathways, but this has not been substantially investigated. In this small study, we seek to identify a molecular signature of zone of origin and relate the signature to clinical factors. The identification of molecular differences between zones could pinpoint a key source of variability in tumor prognosis and treatment response, help expose zone-specific risk factors and partially explain difficulties in identifying reproducible tissue biomarkers of prostate cancer prognosis.
Motivation for this study originated from an earlier prostate tumor gene expression study nested in two large cohort studies, the Physicians' Health Study (PHS) and the Swedish Watchful Waiting Study (5) (6) (7) , in which we saw profound differences in gene expression patterns between the two cohorts. An important distinction between the cohorts was the type of tissue specimen available: the PHS cohort consisted primarily of radical prostatectomies (RPs), whereas the Swedish cohort consisted of men undergoing transurethral resection of the prostate (TURP), a non-curative procedure intended to treat urinary symptoms. The zonal origins of tumors from RPs probably reflect the underlying distribution of tumor zones-i.e. 70-80% PZ, 20-30% TZ. However, because the TZ surrounds the urethra, it is more frequently the location of cancer diagnosed incidentally by TURP (4) . We therefore undertook this study primarily to test whether the expression differences between the TURPs and RPs could be due to expression differences between TZ and PZ tissue.
Methods

Study participants
The primary analysis uses data from three groups of men with gene expression assessed on the Affymetrix GeneChip Human Gene 1.0 ST array. One group consists of five Swedish individuals with no signs of prostate cancer who were undergoing surgical treatment for bladder cancer and whose prostates were removed during the surgery. These prostates were evaluated in the same way as prostatectomy specimens using whole mount slides and no cancer was detected. Three 0.7 mm cores were taken from glandular areas of the TZ and PZ of the prostates of these men, and gene expression assessed on these samples was used to build a signature of zone. The second group consists of nine Swedish individuals with prostate cancer treated by RP whose tumors were located entirely in either the TZ or the PZ. Here, whole mount slides 1 cm apart were used to confirm that the prostate cancer was located in only one zone. Three 0.7 mm cores were taken from the area of the tumor with the highest density of tumor cells. The tissue from these men is used for testing whether the signature of zone built in normal tissue can successfully classify the zone of tumors.
The third group of men providing data for the primary analysis consists of 369 predominantly white USA men with prostate cancer with RP tissue.
Properties of the signature are investigated among these men who come from two USA-based prospective studies that have been ongoing for over 25 years: the PHS and the Health Professionals Follow-Up Study (HPFS). The PHS began in 1986 enrolling 22 071 initially healthy physicians; 7001 additional physicians were added in 1997 (8) . The HPFS is a prospective cohort study that enrolled 51 529 health professionals in 1986 (9) . Men in both studies are followed with regular questionnaires to collect information on diet and lifestyle as well as health outcomes including prostate cancer. When a man is diagnosed with prostate cancer, his medical records and archival tumor tissue are requested from the treating hospital. Among the men with available medical records and tissue, we selected cases using an 'extreme' case-control design in order to facilitate a comparison of lethal and indolent disease. Specifically, if a man died of prostate cancer or developed distant metastases, he was considered a lethal case; if he did not die or develop metastases and survived at least 8 years after diagnosis, he was considered a non-lethal case. These lethal and non-lethal cases were included in our gene expression study; note that the non-lethal cases are a mixture of men who would have survived without treatment and those who have been cured by treatment. Clinical information such as stage and prostate-specific antigen (PSA) at diagnosis was abstracted from medical records, and Gleason score was determined by a standardized review of archival tissue. Two 0.6 mm cores were extracted from regions of high-density tumor (>80% of cells).
Properties of the signature are further investigated in a study using gene expression measured on an Illumina chip designed with ~6000 genes thought to be relevant to cancer. This study included participants from the PHS as well as the population-based Swedish Watchful Waiting Study, which consisted of men diagnosed with incidental prostate cancer discovered through TURP in the Örebro (1977-94) and South East (1987-99) Health Care Regions of Sweden. No PSA screening programs were then in place, and patients were followed expectantly. Archival TURP specimens with high-density tumor regions (>90% of cells) were identified and included. Participants were also selected for lethal and non-lethal phenotypes, as described previously.
Messenger RNA expression profiling
For men in the primary analysis, we utilized archival formalin-fixed paraffin-embedded (FFPE) specimens and undertook whole-genome gene expression profiling. To conduct this profiling in FFPE tissues, whole transcriptome amplification using the WT-Ovation FFPE System V2 (NuGEN, San Carlos, CA) was paired with microarray technologies using the GeneChip Human Gene 1.0 ST microarray (Affymetrix, Santa Clara, CA). For the expression profiles generated, we regressed out technical variables and then shifted the residuals to have the original mean expression values, and normalized using the robust multi-array average method (10, 11) . We mapped gene names to Affymetrix transcript cluster IDs using the NetAffx annotations as implemented in the Bioconductor annotation package pd.hugene.1.0.st.v1; this resulted in 20 254 unique named genes. Further details are available elsewhere (12) .
For men in the secondary analysis, RNA was extracted from FFPE tumor tissue and four complementary DNA-mediated annealing, selection, extension and ligation assay panels were designed for the Illumina platform (Illumina, San Diego, CA) for the discovery of molecular signatures relevant to cancer, as described previously (5) . Mapping the probes to gene names resulted in 6090 named genes. Further details on RNA extraction, sample processing and data normalization may be found elsewhere (5) .
Statistical methods
In our primary analysis, we focused only on men with gene expression assessed using the Affymetrix chip, with measurements on 20 254 genes. To improve our ability to build a meaningful prediction model, we restricted to genes we considered expressed, which we defined as genes with an expression level of at least 5 in at least one individual. This restriction left us with 8041 genes. We then centered the genes to have mean 0.
To build a model for predicting whether tissue comes from the TZ or the PZ, we used a nearest shrunken centroids classifier to predict zone using tissue from the prostates of patients without prostate cancer. A sample from each zone in each individual was included in the gene expression study, for a total of 10 samples. Matching information was not used in model-building; we felt that this choice is reasonable here because we are using these samples only for model-building and not for making any inference, and it in fact biases us towards a null model if there are dominant between-subject effects. The nearest shrunken centroids classifier, called Prediction Analysis of Microarrays, classifies individuals according to whether their gene expression patterns are closer to a TZ archetype or a PZ archetype, where these archetypes are defined using the average pattern of gene expression among the samples from each tissue type on a particular subset of genes (13) . The classifier determines the optimal subset of genes using cross-validation and shrinks the average values towards 0 for model stability. After building the classifier, we can apply it to new individuals to produce an estimated probability that the tissue is from the TZ; we denote this prediction Prob(TZ). When Prob(TZ) is high, the model predicts that the tissue is from the TZ, and when it is low, the model predicts that the tissue is from the PZ. To determine how well this model succeeds in predicting zone in tumor tissue, we applied it to gene expression assessed in prostatectomy samples from nine men with tumors located entirely within one zone: six with TZ tumors and three with PZ tumors. We assessed prediction accuracy using the area under the receiver operating characteristic curve (AUC). After developing and evaluating this gene expression model for tumor zone, we applied it to men in the PHS and HPFS with tumor tissue of unspecified zone for whom gene expression on tumor tissue was assessed on the same chip. Although we do not know tumor location or origin for these individuals, we used our zone prediction Prob(TZ) as an approximation for zone. We were then interested in two major questions. First, we wanted to test whether the predicted zone of origin Prob(TZ) was predictive of lethal versus non-lethal disease and other clinical features such as Gleason score, stage and PSA at diagnosis. To relate Prob(TZ) to risk of lethality, we fit a logistic regression model predicting lethal disease from Prob(TZ) (and cohort-specific intercepts). To relate Prob(TZ) to the categorical clinical features, we fit linear models predicting logittransformed Prob(TZ) (a transformation to yield near-normality) from the clinical factor of interest and cohort-specific intercepts. Second, we were curious whether there might be zone-specific prediction models for lethality. That is, we wondered whether there is a different set of genes that predict lethality among tumors originating in the TZ compared with tumors originating in the PZ. To look at this, we separated the data into two discrete groups: estimated PZ and estimated TZ, which we defined using the samples with known zone: estimated PZ tumors had Prob(TZ) lower than the highest value among known PZ tumors, and estimated TZ had Prob(TZ) higher than the lowest value among known TZ tumors. We built a model predicting lethality among the estimated PZ cases and a second model in the estimated TZ cases. We compared the genes selected in both models to see if they were similar and compared them with the genes in a previously developed 157-gene signature for Gleason score as an exploratory analysis (7) .
Abbreviations
Finally, we returned to the Illumina gene expression data set where we had observed significant differences between men in two cohorts-the PHS RPs and the Swedish TURPs. We quantified the number of significant differentially expressed genes using t-tests to illustrate the strong differences among the 6090 genes available. We reconstructed the model for zone using the normal tissue assessed on Affymetrix, after restricting to genes in the overlap of the 6090 genes available on Illumina and the 8041 genes expressed on the Affymetrix chip. In order to make a model in the Affymetrix data set and apply it to the Illumina data set, we inspected the 65 individuals and 3280 genes in the overlap between the two data sets and decided that if we centered each gene in each platform, we produced sufficiently comparable values of gene expression. We then applied the model to the Illumina gene expression data and assessed how well Prob(TZ) predicted TURP tissue using the AUC.
All analyses were conducted in R (14) . This study was approved by the institutional review boards at the Harvard School of Public Health and Partners Health Care, as well as the ethics committee at Örebro University Hospital.
Results
Model-building and testing
To build the model for predicting zone, we considered samples of normal TZ and PZ prostate tissue taken from five patients with bladder cancer and used a nearest shrunken centroids classifier (13) , finding that a model with 11 genes exhibited good cross-validated prediction accuracy (Figure 1 ). Applying this model to a new individual's gene expression values produces an estimated probability that the tissue is from the TZ, which we denote Prob(TZ); a high value suggests the tissue is from the TZ and a low value suggests it is from the PZ.
To determine how well this model predicted zone in tumor tissue, we applied it to nine tumors located exclusively in a single zone: six TZ tumors and three PZ tumors. Clinical characteristics as well as predictions Prob(TZ) for these men are displayed in Table 1 . In this small sample, prediction was perfect (AUC = 1, P = 0.01). The men with TZ tumors had Prob(TZ) >0.69; the men with PZ tumors had Prob(TZ) below 0.12.
Applying model to tumors with unknown zone
We applied the model to men with tumors of unspecified zone taken from RP samples in the PHS and HPFS with expression assessed on the same chip. Clinical characteristics of these men are displayed in Table 2 . The distributions of predictions Prob(TZ) are shown in Supplementary Figure 1 , available at Carcinogenesis Online. Most of the tumors demonstrate expression profiles similar to PZ tumors, which is consistent with the fact that the majority of tumors originate in the PZ.
We tested whether the predicted zone of origin Prob(TZ) was associated with lethal disease, Gleason score, pathological stage and PSA at diagnosis. The odds ratio of association between Prob(TZ) and lethal disease was 0.43 [95% confidence interval (CI) 0.16-1.14; P = 0.09]. Though not statistically significant, this odds ratio is consistent with previous suggestions that TZ tumors are less lethal than PZ tumors. Relationships with clinical factors are displayed in Figure 2 . Notably, there is a significant association with Gleason (P = 0.009): those with lower Gleason are more like TZ tumors. There is no significant association with stage or PSA at diagnosis.
Next, as an exploratory analysis, we built zone-specific prediction models for lethality. We separated the data into two discrete groups: estimated PZ tumors, with Prob(TZ) ≤ 0. Prob(TZ) ≥ 0.69 (the lowest value among the known TZ samples), yielding 46 cases with eight lethal events. The top-ranked genes in these two models are presented in Table 3 . Although the numbers were so small that we could not with confidence compare the prediction performance of these models, the model built to predict lethality in the TZ-like cases had different genes than the model built in the PZ-like cases. Nine of the top genes that predict lethality among the PZ cases also appear in a previously described signature for high Gleason score (7) , while only two of the top genes that predict lethality among the TZ cases do. However, we cannot rule out that this is due to lack of power to detect a reasonable model, given only eight lethal events.
Applying model to explain differences between RP and TURP
Finally, we returned to our earlier gene expression study where we observed significant differences in expression between men in two cohorts -the PHS RPs and the Swedish TURPs. Clinical covariates are displayed in Table 4 . Among 6090 genes on the Illumina chip, 373 (6.1%) demonstrated significant associations with cohort membership after a Bonferroni correction for multiple testing. To test whether this dramatic difference was due to zone, we reconstructed the model predicting zone using the 3280 genes in the overlap between the 8041 genes used in the primary analysis and the genes on the Illumina chip, which reduced the model to six genes: BMP5, TSPAN8, FOLH1, LAMA2, CPA3 and TFPI. We evaluated how well the model for TZ predicted TURP tissue in this data, finding excellent prediction (AUC = 0.87, P < 0.0001). This suggests that one major contributor to the observed differences in expression between these cohorts is zone. Even after controlling for Prob(TZ), however, a substantial number of genes remain differentially expressed between the cohorts [169 out of 6090 (2.8%), after Bonferroni correction], suggesting that other factors also contribute to the differences in expression between TURP and RP samples.
Discussion
In this study, we investigated whether we could use gene expression to predict the zone in which a tumor originates. Although previous studies have identified expression differences by zone in normal tissue (15, 16) , we found that a signature for zone-based on normal tissue expression perfectly classified nine tumors located in one zone or the other. Virtually all previous studies define tumor zone as the zone in which 70% of the tumor lies, but we were concerned that this definition may result in misclassification. Thus, our test set consisted of tumors completely contained within a single zone. Because zonal expression differences in benign tissue persisted in tumor tissue, the genes themselves may not only be of interest for prediction, but may also have a role in zone-specific susceptibility to prostate cancer. Among the top genes in our model for zone, BMP5 (bone morphogenetic protein 5) and FOLH1, also known as PSMA (prostate-specific membrane antigen) stand out. There has been interest in BMP genes in prostate and other cancers because they may influence metastases to bone, which is the most common site of metastasis in prostate cancer (17) ; PSMA has also been implicated in prostate cancer (18) . We further investigated whether the zonal signature was related to clinical features when applied to tumors with unknown zone and found that among 369 such RP samples, tumors that molecularly resembled TZ tumors showed a nonsignificant trend to lower risk of mortality (P = 0.09) largely explained by their generally more favorable Gleason scores (P = 0.009), consistent with previous assumptions that TZ tumors tend to have less lethal potential than PZ tumors. The reduced lethality among TZ tumors has been attributed previously to the fact that they are located in an area of the prostate from which it is difficult to spread. Our study suggests that there might also be molecular distinctions. Although identifying zone of origin by eye can be difficult or impossible depending on the tissue type available and the tumor size, a molecular signature such as that proposed here could permit identification of zone of origin for all tumors. With further investigation, this work could have clinical utility, if identification of zone of origin itself proves useful in predicting prognosis or if other prognostic markers vary by zone of origin.
It was with this idea in mind-that the prognostic significance of clinical features or genes could vary depending on where the tumor originated-that we performed the exploratory analysis summarized in Table 3 , in which we divided the tumors of unknown zonal origin into those resembling TZ tumors and those resembling PZ tumors, and developed models predicting lethality within those groups. If PZ tumors and TZ tumors progress along similar pathways, we would expect similar genes to appear in models predicting prognosis in these two groups; however, none of the genes selected into the models overlapped. Alternatively, as Gleason is such a strong predictor of disease course, we assumed that the genes in a previously developed signature predicting Gleason score (7) might appear in both zonal models; however, we find that although these Gleasonrelated genes dominate the model among PZ-like tumors, they are not as prominent in the model among TZ-like tumors. Because the sample sizes (and numbers of lethal events) are limited in these two groups, these results should be interpreted cautiously. However, they support the hypothesis that meaningfully separating tumors based on zone of origin and developing prediction models separately by zone could potentially improve our ability to predict outcomes by illuminating some previously unobserved intertumor heterogeneity. The zonal signature also demonstrated success discriminating between RP samples and TURP samples, suggesting that some expression differences between these samples may be due to zone. Although zone does appear to be an important contributor, a substantial number of genes unrelated to zone were also differentially expressed. Other factors such as sample processing and fixation may also contribute. This finding has implications for gene expression signature discovery and validation.
When our signature was applied to specimens where tumor zone of origin was unknown, as frequently occurs in practice, our signature produced zone predictions Prob(TZ) on a spectrum between 0 and 1. The predictions at the ends of this spectrum are consistent with patterns from tumors with known zone; however, it is unclear how best to interpret values in the middle of the spectrum. When a tumor originates in one zone and spreads into the other, does its gene expression begin to take on aspects of the new zone? Do there exist additional tumor subtypes that exhibit less 'preference' for a particular zone? Our study is not able to directly address these possibilities. Thus, although we hypothesize that our signature is capturing 'zone of origin,' we cannot rule out that it is only capturing 'zone of current location,' and follow-up studies of tumors involving both zones where zone of origin can be guessed with confidence are needed to distinguish these possibilities.
Our study has several other limitations. We cannot confirm that the gene expression differences are driven by expression in tumor cells or whether they result from contamination by benign tissue. Although we ensured high proportions of tumor cells in our samples, there may be small numbers of normal cells that contribute to the signal we observe in the gene expression. Further studies using microdissection are needed to investigate this issue. Another potential concern is that the signature is simply detecting Gleason score rather than tumor zone. We doubt that the score is directly confounded by Gleason because it was built in benign tissue; moreover, our test set of tumors, while not having matched distributions of Gleason score, at least demonstrate a variety of Gleason scores-6, 6, 7, 7, 7, 9; mean 7 among the TZ samples and 7, 8, 8; mean 7.7 among the PZ samples. However, further signature development and evaluation are certainly needed to determine whether a zonal signature can provide any prognostic information beyond Gleason score. Finally, as mentioned, this study was undertaken as a small study to test whether gene expression differences in TZ and PZ tissue could explain some of the differences observed in Swedish TURP samples and USA RP samples, rather than to fully explore the potential for molecular differences between zones. Thus, although our findings are suggestive, larger studies are needed to identify a robust signature of zone of origin, and to determine its clinical relevance and meaningful cutpoints. Investigations of the signature in cell lines could also help illuminate the signature's significance. In this work, we are putting forward evidence that understanding molecular zonal distinctions might be a fruitful direction to pursue. In particular, we would like to advocate that tumor zone be included among commonly reported clinical features when available because this could provide an avenue for interesting follow-up.
This study has numerous strengths, including the incorporation of comprehensive gene expression data, the use of tumors contained entirely in one zone to reduce misclassification and the ability to investigate signature properties in a large cohort of tumor specimens with unknown zonal origin and long-term follow-up. In addition, we used RP specimens to build the model, removing the potential impact of the TURP procedure itself on gene expression levels.
This study supports our initial hypothesis that zone of origin significantly contributes to molecular differences between TURP-and RP-derived tumors, which may have more widespread implications in epidemiological and clinical studies. First, understanding expression patterns consistent with a particular zone could clarify situations where studies based on TURPs and studies based on RPs produce apparently inconsistent results. For example, there is some evidence that an association may exist between the TMPRSS2:ERG fusion and survival in TURP cohorts but not RP cohorts. Specifically, in a meta-analysis, men treated by RP with the TMPRSS2:ERG fusion were no more likely to have high Gleason score [risk ratio (RR) = 0.85, 95% CI 0.72-1.01, N = 3803] or to die of prostate cancer (RR = 0.99, 95% CI 0.47-2.09, N = 2049) than those without it, whereas among the substantially fewer men diagnosed by TURP, the fusion was associated with higher Gleason (RR = 1.61, 95% CI 1.01-2.57, N = 581) and non-significantly with higher lethality (RR = 1.37, 95% CI 0.53-3.51) (19) . It is also thought that the fusion is rare in TZ tumors compared with PZ tumors (20, 21) . Perhaps among TURP cohorts, the fusion in fact marks tumors of PZ origin, which may have an increased risk of lethality, and thus the moderate association between the fusion and lethality in TURP cohorts is due to confounding by tumor zone. A signature of zone of origin could help control for the effects of zone in such studies. Second, if an association between prognosis and a zonal signature is established in larger studies, such a signature could potentially identify zone of origin and help characterize aggressive potential in TURP and biopsy specimens where only a small portion of the prostate is sampled. Finally, a lack of appreciation for subtypes of prostate cancer with distinct etiologies may contribute to the paucity of established risk factors. Future studies that relate exposures to zone-based subtypes of prostate cancer could identify new zone-specific risk factors. Table 3 . Genes in the zone-specific models for lethality in order of importance, together with indications of direction of association with lethality, and whether the genes belong to the model for zone (Figure 1 ), or the model for Gleason (7) Genes in the model for lethality built in estimated PZ cases Genes in the model for lethality built in estimated TZ cases
Genes in the signature of Gleason grade (7) . 
